Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies

Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.

Inclusion Criteria: * Patients aged between 18 and 65 years. * Caucasian ethnicity. * Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3). * Have at least one year of history of migraine. * Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody. * Patients able to describe their clinical situation and the characteristics of their headache. * Grant your informed consent. Exclusion Criteria: * Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication. * Neurological focus in the examination. * Pregnancy or breastfeeding period. * Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study. * Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies. * Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.